# Association of mitochondrial DNA copy number with

## cardiometabolic diseases in a large cross-sectional study of

## multiple ancestries

Xue Liu<sup>1</sup>, Ryan J. Longchamps<sup>2</sup>, Kerri Wiggins<sup>3</sup>, Laura M. Raffield<sup>4</sup>, Lawrence F. Bielak<sup>5</sup>, Wei Zhao<sup>5</sup>, Achilleas Pitsillides<sup>6</sup>, Thomas Blackwell<sup>7</sup>, Xiuqing Guo<sup>8</sup>, Nuzulul Kurniansyah<sup>9</sup>, Bharat Thyagarajan<sup>10</sup>, Nathan Pankratz<sup>11</sup>, Stephen S. Rich<sup>12</sup>, Kent D. Taylor<sup>8</sup>, Patricia A. Peyser<sup>5</sup>, Susan R. Heckbert<sup>3</sup>, Sudha Seshadri<sup>13</sup>, L Adrienne Cupples<sup>6</sup>, Eric Boerwinkle<sup>14</sup>, Megan L. Grove<sup>14</sup>, Nicholas Larson<sup>15</sup>, Jennifer A. Smith<sup>5</sup>, Ramachandran S Vasan<sup>16,17</sup>, Tamar Sofer<sup>9,18</sup>, Annette L Fitzpatrick<sup>19</sup>, Myriam Fornage<sup>20</sup>, Jun Ding<sup>21</sup>, Adolfo Correa<sup>22</sup>, Gonçalo Abecasis<sup>7</sup>, Bruce M. Psaty<sup>3,23</sup>, James G. Wilson<sup>24</sup>, Daniel Levy<sup>16,25</sup>, Jerome I. Rotter<sup>8</sup>, Joshua C. Bis<sup>3</sup>, †Claudia L Satizabal<sup>13</sup>, †Dan E. Arking<sup>2</sup>, and †Chunyu Liu<sup>6</sup>

Representing the TOPMed mtDNA Working Group
NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium

<sup>1</sup>Boston University School of Medicine, Department of Medicine, Boston, MA 20118, USA;

<sup>2</sup>McKusick-Nathans Institute, Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, MD 21205, USA;

<sup>3</sup>Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, WA 98101, USA

<sup>4</sup>Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA;

<sup>5</sup>University of Michigan School of Public Health, Department of Epidemiology, Ann Arbor, MI 48109, USA;

<sup>6</sup>Department of Biostatistics, School of Public Health, Boston University, Boston, MA 02118, USA;

<sup>7</sup>TOPMed Informatics Research Center, University of Michigan, Ann Arbor, MI 48109, USA;

<sup>8</sup>The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA 90502, USA:

<sup>9</sup>Brigham and Women's Hospital, Boston, MA 02115, USA;

<sup>10</sup>Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA;

<sup>11</sup>Department of Computational Pathology, University of Minnesota, Minneapolis, MN 55455

<sup>12</sup>Department of Public Health Services, Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22908, USA;

<sup>13</sup>University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA;

<sup>14</sup>Department of Epidemiology, Human Genetics and Environmental Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA;

<sup>15</sup>Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA

<sup>16</sup>Framingham Heart Study, NHLBI, Framingham, MA, USA.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- <sup>17</sup>Sections of Preventive Medicine and Epidemiology, and Cardiovascular Medicine, Boston University School of Medicine, Boston, MA, USA.
- <sup>18</sup>Harvad Medical School, Boston, MA 02115, USA;
- <sup>19</sup>University of Washington School of Public Health, Department of Epidemiology, Seattle, WA 98101, USA;
- <sup>20</sup>Center for Human Genetics, University of Texas Health Science Center at Houston, Houston, TX 77030, USA:
- <sup>21</sup>Laboratory of Genetics and Genomics, NIA/NIH, Baltimore, MD 21224
- <sup>22</sup>Department of Medicine, University of Mississippi Medical Center, Jackson, MS, 39216, USA;
- <sup>23</sup>Kaiser Permanente Washington Health Research Institute, Seattle, WA 98101, USA;
- <sup>24</sup>Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS
- <sup>25</sup>The Framingham Heart Study, Framingham, MA 01702, USA;
- <sup>26</sup>Population Sciences Branch National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA;
- <sup>†</sup> These authors contribute equally to this work

## **Abstract**

The mitochondrial genome (mtDNA) is represented at variable copy number (CN) in human cells and plays essential roles in cellular metabolism. Previous studies reported inconsistent associations between mtDNA CN and cardiometabolic disease (CMD) traits. We determined the cross-sectional association of mtDNA CN measured in whole blood with several CMD traits in ~66,100 individuals (mean age 60, 54% women, and 21% non-European ancestries). Cohort- and ancestry-specific association and meta-analysis were performed adjusting for trait-specific covariates and batch. Because white blood cell (WBC) count, a marker of subclinical inflammation, is associated with mtDNA CN level and multiple CMD traits, we further compared associations with and without adjustment for WBCs in a subset of individuals with WBCs. In meta-analysis without cell count adjustment in European ancestry (EA) participants (n=52,500), lower mtDNA CN was associated with higher odds of obesity (OR with 95% CI=1.13 (1.11, 1.16), P=3.3e-30) and hypertension (OR=1.05 (1.03, 1.08), P=4.0e-07). Further adjusting for WBCs in a subset of EA participants (N=44,100), associations became non-significant (P>0.05) for hypertension, attenuated for obesity (ORwithout cell counts=1.15 (1.12, 1.18) versus ORcell counts=1.06 (1.03, 1.08)) but strengthened for hyperlipidemia (ORwithout cell counts =1.03 (1.00, 1.06) versus ORcell counts =1.06 (1.03, 1.09)). The magnitude and directionality of most associations were consistent between participants of European and other ancestries. Understanding the role of mtDNA CN in CMD

will provide insight into the pathobiology underlying metabolic diseases. Further

research on modifiable factors that influence mtDNA CN may help develop

therapeutic strategies for preventing and treating metabolic diseases.

Key words: mitochondrial DNA copy number, cardiometabolic disease, whole

4

genome sequencing

## Introduction

As the powerhouse of eukaryotic cells, mitochondria convert dietary calories to molecular energy through oxidative phosphorylation (OXPHOS).<sup>1</sup> In addition, mitochondria play essential roles in cellular differentiation, proliferation, reprogramming, and aging.<sup>2-7</sup> Mitochondria contain their own genome (mtDNA) which is a circular, double-stranded DNA molecule of 16.6 kb. mtDNA encodes 13 key OXPHOS proteins, 22 transfer RNAs (tRNAs), and two ribosomal RNAs (rRNAs)<sup>1</sup>. Multiple copies of mtDNA are present per mitochondrion, and cells contain up to 7000 mitochondria per cell<sup>8</sup>. The mtDNA copy number (mtDNA CN) correlates with cellular ATP generating capacity and metabolic status,<sup>9</sup> and therefore, varies greatly across tissue and cell types depending on cellular energy demand.<sup>1,10,11</sup>

Several previous studies have demonstrated that mtDNA CN is lower in older individuals and this decrease is associated with a general decline in health. 12-14 In age- and sex-matched case-control studies (55/29 and 147/170 cases/controls, respectively), mtDNA CN was found to be significantly lower in individuals with diabetes than controls. 15,16 Lower mtDNA content was also related to higher fasting blood glucose (FBG), hemoglobin A1c (HbA1c), and lipid levels including high density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides (TRIG), and total cholesterol (TC) in both diabetic patients and controls. 15 In addition, mtDNA content was inversely related to BMI and fat

accumulation in 94 healthy young individuals (mean age 30 years).<sup>17</sup> A more

recent study in two independent cohorts of women of European ancestry

(n=2,278, mean age 30 years; and n=2,872, mean age 69 years), however,

failed to detect significant associations between mtDNA CN and

cardiometabolic risk factors including systolic blood pressure (SBP), diastolic

blood pressure (DBP), HDL, LDL, TRIG, and glucose levels. 18

Given inconsistent findings in previous studies and the central role of

mtDNA in metabolism, we set out to investigate the association between

mtDNA CN and several cardiometabolic risk factors in seven US cohorts

representing several ancestries with whole genome sequencing (WGS) and

extensive cardiometabolic phenotyping. We also included individuals with

Whole Exome Sequencing (WES) from the UK Biobank for validation. To

minimize bias, we used a pre-specified plan to harmonize phenotypes and

implement consistent procedures in quality control and statistical analysis

across all cohorts. We performed cohort- and ancestry-specific association

analysis between mtDNA CN and several cardiometabolic disease phenotypes.

We also performed meta-analysis in participants of European and African

6

American ancestry, and across ancestries.

Methods

Study participants

This study included up to 27,000 individuals with WGS in the NHLBI's Trans-Omics for Precision Medicine (TOPMed) program (67.4% women; age range of 20-100 years; 45.4% European, 32.6% African-American, 19.6% Hispanic and 2.4% Chinese ancestry) (**Supplemental Table 1**). Additionally, we included up to 39,100 participants of European ancestry from the UK Biobank with WES (54% women; 40-75 years; 100% Europeans) for validation (**Supplemental Table 1**). All study participants provided written informed consent for genetic studies. The protocols for WGS and WES were approved by the institutional review boards (IRB) of the participating institutions (**Supplemental Materials**).

#### mtDNA copy number estimation

mtDNA CN estimation in WGS: whole blood derived DNA was used for WGS through TOPMed sequencing centers. The average coverage was ~39x across samples. The program fastMitoCalc of the software package mitoAnalyzer was used to estimate mtDNA copy number across TOPMed participants.<sup>13</sup> The average mtDNA CN per cell was estimated as twice the ratio of average coverage of mtDNA to average coverage of the nuclear DNA (nDNA). The coverage was defined as the number of reads that were mapped to a given nucleotide in the reconstructed sequence.<sup>13</sup>

mtDNA CN estimation in UK Bank: whole blood derived DNA was used for WES in UK Bank. mtDNA CN estimates were generated by customized regression with specific terms in Perl and R software using Exome SPB CRAM files (version Jul 2018) downloaded from the UK Bank data repository (Supplemental Materials).

mtDNA CN estimation in ARIC using other methods: mtDNA CN estimation from low-pass WGS was calculated as the ratio of mitochondrial reads to the number of total aligned reads (**Supplemental Materials**). mtDNA CN estimated from the Affymetrix Genome-Wide Human SNP Array 6.0 was calculated using Genvisis 15 software package (**Supplemental Materials**). The participants whose mtDNA CN were estimated from low-pass WGS and Affymetrix Genome-Wide Human SNP Array 6.0 were independent to each other and were independent to those with TOPMed WGS in the ARIC cohort, as previously described (**Supplemental Materials**).

#### Metabolic disease phenotypes

All outcome variables were mapped to the examinations when blood was drawn for DNA extraction for mtDNA CN estimates. Our primary analysis focused on four cardiometabolic disease phenotypes, obesity, hypertension (HTN), type 2 diabetes (T2D), and hyperlipidemia. Obesity was defined as body mass index (BMI) ≥30 (kg/m²). T2D was defined as fasting blood glucose ≥126 mg/dL or currently receiving glucose-lowering or diabetes medication (s). Hypertension

(HTN) was defined as systolic blood pressure (SBP) ≥140 mmHg, or diastolic blood pressure (DBP) ≥90 mmHg, or use of antihypertensive medication(s) for blood pressure control. Hyperlipidemia was defined as fasting total cholesterol (TC) ≥200 mg/dL or triglyceride (TRIG) ≥150 mg/dL, or use of any lipid-lowering medication.

We also analyzed the association of mtDNA CN with continuous cardiometabolic traits: BMI, SBP, DBP, FBG, HDL cholesterol, LDL cholesterol, and TRIG levels. In the analysis of FBG, we excluded individuals with diabetes, defined as glucose value ≥126 mg/dL and/or taking glucose-lowering or diabetes medications.<sup>20</sup> SBP and DBP values (mmHg) were derived from the averages of two measurements. We added 15 mmHg and 10 mmHg to SBP and DBP, respectively, for individuals taking any BP lowering medications.<sup>21</sup> The total cholesterol (TC) measurements were divided by 0.8 for individuals using lipid treatment medications.<sup>22</sup> LDL (mg/dL) was calculated as (TC - HDL - TRIG/5) in individuals with TRIG <400 mg/dL using imputed TC values.<sup>22</sup> In analyses of FBG and lipid levels, we excluded individuals whose fasting status was not established. TRIG, LDL and HDL values were log-transformed to approximate normality. Other continuous outcome variables were not transformed.

Metabolic syndrome is a collection of risk factors that increase the risk for cardiovascular disease.<sup>23</sup> We analyzed the presence of metabolic syndrome

variable in relation to mtDNA CN. An individual was classified as having metabolic syndrome (0/1) if he/she had three of the five following conditions: <sup>23</sup> 1) obesity – waist circumference >40 inches in men and >35 inches in women; 2) hyperglycemia – fasting glucose ≥100 mg/dL or currently receiving glucoselowering or diabetes medication; 3) dyslipidemia – triglyceride ≥150 mg/dL or on lipid-lowering treatment; 4) dyslipidemia – High density lipoprotein cholesterol <40 mg/dL in men or <50 mg/dL in women or on lipid-lowering treatment; and 5) hypertension – 130 mmHg systolic or >85 mmHg diastolic or the current use of antihypertensive medication (s). Of note, the thresholds in defining metabolic syndrome are different from those for individual disease phenotypes in our primary analysis. Waist circumference was not measured in approximately a third of the FHS participants. Because BMI is the most common measure of overall obesity<sup>24</sup>, to increase the sample size we used BMI ≥30 to define obesity in FHS participants with missing waist circumference values.

Statistical analysis

In all analyses, we used mtDNA CN as the primary independent variable. To identify confounders and covariates in association analyses, we first examined whether mtDNA CN levels were associated with 'blood collection year' (the year when blood was drawn, as a surrogate of batch effects for blood-derived DNA samples) in all participating cohorts. We also investigated whether mtDNA CN

10

was associated with blood cell counts in cohorts with imputed or measured cell count variables available (**Supplemental Table 2**)<sup>25,26</sup>. We further examined mtDNA CN in relation to age and sex after adjusting for blood collection year (**Supplemental Figure 1**).

Based on observing significant associations of mtDNA CN in relation to 'blood collection year', age and sex, we generated mtDNA CN residuals for downstream analyses by regressing mtDNA CN on age, age squared, sex and blood collection year (as a factored variable) in each cohort. The residuals were standardized to a mean of zero and standard deviation (s.d.) of one, and used as the main predictor in all regression models. In the primary analysis, we used logistic regression (for unrelated individuals) and mixed effects logistic regression model (related individuals) to analyze binary outcomes (i.e., obesity, HTN) in relation to mtDNA CN residuals. Because age, sex and BMI are important confounders or covariates for cardiometabolic traits, we further adjusted for sex and age as covariates in the analysis of obesity, and adjusted for sex, age, age-squared (only for HTN) and BMI as covariates in the analysis of T2D, hyperlipidemia, and HTN. We used linear effects models to analyze continuous outcome variables, adjusting for the same set of covariates as for the respective binary outcomes. For cohorts with family structure, we accounted for maternal lineage as random effects in linear or logistic mixed models. A

maternal lineage was defined to include a founder woman with all of her children, and all grandchildren from daughters of the founder woman.<sup>27</sup>

We performed ancestry-specific meta-analysis with fixed effects (P<sub>Q</sub>>0.01) or random effects (P<sub>Q</sub>≤0.01) inverse variance method to combine results within TOPMed cohorts. We used EA-only meta-analysis in TOPMed as the discovery phase. The UK Biobank participants of European origin were used for validation of results in the discovery phase. We further compared EA only meta-analysis results to those from other ancestries in TOPMed cohorts. Finally, we performed inverse-variance meta-analysis to combine results of all ancestries from TOPMed and UK Biobank. The primary results included associations of mtDNA CN with the four disease outcomes. We used p=0.01 for significance to account for multiple testing for primary results, and used p=0.05/9~0.006 for significance in analysis of continuous outcomes.

White blood cell (WBC) counts were previously reported to be associated with mtDNA CN.<sup>19,28</sup> Measured and/or imputed WBC variables were available in a subset participants in TOPMed and in all participants in UK Biobank. We compared associations between mtDNA CN and individual outcomes in the same participants with and without cell counts as additional covariates. Finally, we investigated whether sex or age modified the association between mtDNA CN and outcome variables. The statistical software R (version 3.6.0) was used for all statistical analyses.

## Results

#### **Characteristics of Study Participants**

The current study included ~52,500 European ancestry (EA) (54% women), ~8,100 African American (AA) (60% women), ~600 Chinese ancestry (EAS) (50% women), and ~4,900 Hispanic ancestry (HA) (58% women) participants with a mean age of 60 years (range 20 to 100 year; **Supplemental Table 1**). We observed moderate to high heterogeneity in distributions of age, sex, and cardiometabolic phenotypes across cohorts and ancestries. For example, the age range was 20 to 100 years in the Framingham Heart Study (FHS) (mean age 60 years, 40% pariticipants≥65 years). In contrast, all participants in the Cardiovascular Health Study (CHS) were older than 65 year of age (mean age 74). HTN, obesity, T2D, and hyperlipidemia were more prevalent in participants of African descent than European, Chinese and Hispanic ancestry. (**Supplemental Table 1**)

#### An inverted U-shape relationship between mtDNA CN and age

We observed that, on average, age was associated with 0.032 s.d. / 10 years higher (95% CI= (0.013, 0.052), P=0.0014) level of mtDNA CN from 20s to 65 years, and 0.14 s.d. / 10 years lower level of mtDNA CN after 65 years (95% CI= (-0.18, -0.10), P=1.82e-13) (**Figure 2**). The relationship between mtDNA CN and age appeared to be similar in men and women. Women had higher mtDNA CN than men (beta=0.23, 95% CI= (0.20, 0.26), P=7.4e-60) as noted

previously.<sup>13,28</sup> The inverted U shape relationship between mtDNA CN and age was slightly attenuated after adjusting for WBC counts (**Supplemental Figure 2**).

Discovery meta-analysis of TOPMed cohorts of European ancestry

We performed the discovery meta-analysis of EA participants in TOPMed (N =13,400). Because lower mtDNA CN was associated with older age and reported to be associated with higher cardiometabolic disease risk, 15-18 we report beta estimates as the change in an outcome variable in response to 1 s.d. lower mtDNA CN in all of analyses. We found that 1 s.d. lower in mtDNA CN was significantly associated with 1.08-fold odds of obesity (95% CI= (1.03, 1.13), P=5.0e-04), 1.07-fold odds of hypertension (95% CI= (1.03, 1.12), P=1.4e-03), 1.16-fold odds of metabolic syndrome (95% CI= (1.06, 1.27), P=1.8e-03). We also found that 1 s.d. lower mtDNA CN was nominally (0.01 < P < 0.05) associated with 1.18-fold odds of diabetes (95%= (1.01, 1.37), P=0.041). For continuous traits, 1 s.d. lower in mtDNA CN was significantly associated with 0.033 mg/dL (95% CI= (0.023, 0.041), P=1.7e-04) higher TRIG and nominally associated with 0.38 mmHg (95% CI= (0.021, 0.73), P=0.038) higher SBP and 0.22 kg/m<sup>2</sup> (95% CI= (0.074, 0.25), P=0.028) higher BMI. mtDNA CN was not significantly associated with DBP, HDL, LDL, or fasting glucose (P>0.05) in the discovery meta-analysis (**Table 1**, **Figures 3 and 4**)

Bidirectional replication with EA participants between TOPMed and UK Biobank and meta-analysis

Most of the significant associations in the discovery phase meta-analysis were validated in the UK Biobank EA sample (**Table 1**). Compared to those in the discovery meta-analysis, the UK Biobank yielded larger effect sizes for associations of several traits (**Supplemental Figure 3**). For example, 1 s.d. lower mtDNA CN was associated with 1.15-fold (95% CI= (1.12, 1.18)) odds of obesity in the UK Biobank versus 1.08-fold (95% CI= 1.03-1.13) in the TOPMed EA-specific meta-analysis. Additionally, 1 s.d. unit lower mtDNA CN was associated with 0.32 kg/m² higher BMI in UKB (p = 9.1e-42) compared to 0.22 kg/m² higher BMI (p=0.028) in the meta-analysis of TOPMed EA participants. DBP and FBG were not significant in the discovery TOPMed EA meta-analysis (beta=0.02, 95% CI= (-0.37, 0.41) with P= 0.92 for DBP; beta=0.067, 95% CI= (-0.11, 0.25) with P=0.47 for FBG) while significant in UK Biobank (beta=0.19, 95% CI= (0.086, 0.30) with P=0.00038 for DBP; beta=0.20, 95% CI = (0.093, 0.30) with P=2.0e-4 for FBG) (**Table 1**).

We performed meta-analysis of all EA participants in the discovery and validation samples (n=52,500) using fixed effects inverse-variance method to combine results (**Table 1**). One s.d. lower mtDNA CN was significantly associated with higher odds of obesity (OR=1.13, 95% CI= (1.11, 1.16), P=3.3e-30), hypertension (OR=1.05, 95% CI= (1.03, 1.08), P=4.0e-07),

metabolic syndrome (OR=1.13, 95% CI= (1.11, 1.16), P=9.7e-27), and nominally associated with diabetes (OR=1.05, 95% CI= (1.00, 1.10), P=0.051), hyperlipidemia (OR=1.03, 95% CI= (1.00, 1.05), P=0.023). For continuous phenotypes, 1 s.d. lower mtDNA CN was significantly associated with 0.15 mmHg higher DBP (95% CI=(0.056, 0.25), P=1.9e-03), 0.42 mmHg higher SBP (95% CI= (0.26, 0.59), P=6.0e-07), 0.32 kg/m² higher BMI (95% CI=(0.27, 0.36), P=2.5e-41), 0.16 mg/dL higher fasting glucose (95% CI= (0.069, 0.25), P=5.4E-04), and 0.025 mg/dL higher triglycerides (95% CI= (0.021, 0.029), P=8.3e-30). mtDNA CN estimated from low-pass WGS and Affymetrix Genome-Wide Human SNP Array 6.0 gave rise to consistent associations for most of the CMD traits compared to that from WGS (Supplemental Table 7).

Comparison of results between EA and other ancestries and metaanalysis of multi-ancestries

The directionality of associations of mtDNA CN with CMD traits were consistent in African American (N=8,100), Hispanic (N=4,900) and East Asian Ancestries (N=600) compared to EA-only meta-analyses for most of the phenotypes (Table 1, Figure 5 and Supplemental Table 3, 4, Supplemental Figure 4, 5). In the meta-analysis of AA participants, 1 s.d. lower mtDNA CN was significantly associated with 1.14-fold odds of diabetes (95%Cl= (1.06, 1.22), P=2.5e-04) and a 0.68 mmHg higher in SBP (95% Cl= (0.21, 1.15), P=4.0e-03). In Asian-only TOPMed participants (n=601), 1 s.d. lower mtDNA CN was

significantly associated with 1.43-fold odds of hyperlipidemia (95% CI= (1.19, 1.72), P=0.00014). In Hispanic-only TOPMed participants (n=4,900), One s.d. lower mtDNA CN was significantly associated with higher odds of diabetes (OR=1.16, 95%CI= (1.06, 1.26), P=0.0012), and significantly associated with 0.019 s.d. lower LDL (95 % CI= (-0.029, -0.0079), P=6.6e-04) and 0.028 s.d. higher TRIG (95% CI= (0.010, 0.046), P=0.0020). (Supplemental Table 4). Results of meta-analysis in pooled-samples are included in Supplemental Table 5.

#### Accounting for cell counts as additional covariates

Cell counts were available for a subset of participants in TOPMed (n=~16,100) and for all of the UK Biobank participants (n=~39,000). Cell counts were inversely related to WBC count and differentials (Supplemental Table 2), which were consistent to previous studies.<sup>29-34</sup> Because WBC count is associated with mtDNA CN and also an indicator of a systemic subclinical inflammation state that accompanies CMD risk factors.<sup>35-39</sup> <sup>40-42</sup> To minimize confounding, we compared results between models with and without WBC cell counts and differentials as additional covariates in meta-analysis of the same individuals in EA. Directionality remained the same for all associations except for HDL after adjusting for cell counts (Supplemental Table 6, Supplemental Figure 6, 7). Comparison of regression coefficients of mtDNA CN with cardiometabolic traits not adjusting for cell counts vs adjusting for cell counts in

other ancestries were available in **Supplemental Figure 8**, **9**. Non-lipid CMD traits and TRIG attenuated their associations with mtDNA CN after adjusting for WBC cell counts and differentials. For example, the association of mtDNA CN with obesity was attenuated: ORwithout cell counts=1.15 (1.12, 1.18), P=7.7e-31 versus ORcell counts=1.06 (1.03, 1.08), P=2.5e-06. In contrast, hyperlipidemia and LDL were not significantly associated with mtDNA CN before adjusting for cell counts (P>0.05) and became significant after adjusting for cell counts (OR=1.06 (1.03, 1.09), P=3.9e-05 for hyperlipidemia and beta=0.012 (0.0096, 0.015), P=7.8e-18 for LDL) (**Supplemental Table 6**).

#### Interaction analyses

We investigated if sex and age modified the relationship of mtDNA CN with cardiometabolic phenotypes. We did not find statistically significant interactions between sex and mtDNA CN, or between age and mtDNA CN with respect to the phenotypes tested (**Supplemental Table 8**).

#### **Discussion**

We demonstrated that lower mtDNA CN is significantly associated with higher level of cardiometabolic disease risk factors in ~66,100 individuals representing multiple ancestries. Consistent effect estimates were obtained from the discovery meta-analysis and the validation cohort of UK Biobank participants with adjustment for traditional covariates as well as adjustment for cell counts, demonstrating the robustness of our findings. The fact that lower mtDNA CN

was significantly associated with higher prevalence of metabolic syndrome further suggests that altered levels of mitochondrial energy production may be associated with a cluster of conditions that increase the risk of cardiovascular disease.

Inflammation is our body's way of protecting itself from harmful stimuli, through regulation of our immune system. WBC count is a blood biomarker of systemic inflammation. It has been increasingly recognized that chronic low-grade inflammatory state accompanies CMD risk.<sup>35</sup> Previous studies found that higher level of WBC counts is associated with increased level of BMI/obesity, 36,37 insulin tolerance and diabetes, 35,38,39 high BP and hypertension. 40-42 In contrast, lipid levels display heterogeneous relationship with WBC. Higher LDL levels are associated with lower total WBC counts, while higher TRIG is associated with higher total WBC counts.<sup>43</sup> On the other hand, this study and previous studies showed that higher WBC were associated with lower mtDNA CN.<sup>29-34</sup> Therefore. the connections among mtDNA CN in whole blood, inflammation, and metabolic disease phenotypes are complex. We compared associations between mtDNA CN and CMD traits with and without adjustment of WBC counts, and found that the strength of associations were attenuated for BMI/obesity, FBG/diabetes, and blood pressure/Hypertension but augmented for LDL and hyperlipidemia. Our findings demonstrated that mtDNA CN in whole blood and WBC count may interplay with CMD traits, especially LDL and hyperlipidemia. Further studies

are warranted to investigate underlying molecular mechanisms to establish a potential causal pathway among mtDNA CN, inflammation and CMD risk.

Most previous studies reported a tendency toward lower mtDNA CN with advancing age, <sup>12,13,19,28,44,45</sup> The current cross-sectional study, using a large sample size with a wide age range, demonstrated that mtDNA CN increases slightly from young adult (age 20 to 29) to late middle age (65 years old), and decreases in individuals older than 65 years. Most of the previous studies included participants with a limited age range with the majority of study participants being young, middle-aged, or older individuals. <sup>12,45,46</sup> In addition, these studies only investigated the linear relationship between mtDNA CN and age. <sup>12,13,19</sup> The inverted U shape relationship was only discovered when we examined mtDNA CN in relation to age by decade. This study only investigated age-mtDNA CN association cross-sectionally. The intra-individual mtDNA CN variability with advancing age needs to be explored in a longitudinal setting in future studies.

**Strengths and Limitations** 

This study includes a large sample size of men and women of multiple ancestries across a wide age range, thus enables us to investigate the relationships of mtDNA CN with cardiometabolic phenotypes throughout the adult life span. In addition, we performed careful phenotype harmonization and

20

examined several potential confounding variables of mtDNA CN in association analysis with metabolic traits. Furthermore, we included association analyses of CMD traits with mtDNA CN estimated from several technologies further demonstrated the utility of mtDNA CN estimated from these different technologies in association analysis. Despite the multiple strengths in this study, several limitations should be noted. mtDNA CN was estimated using DNA derived from whole blood, which is not necessarily the relevant tissues with respect to cardiometabolic (e.g., cardiac muscle, skeletal muscle, adipose tissue) and aging-related (e.g., brain) disease phenotypes. Nevertheless, peripheral blood is easily accessible, and our aim was to evaluate mtDNA CN as a biomarker of disease phenotypes. Second, though we accounted for confounders and known batch effects in mtDNA CN and harmonized metabolic traits, we still observed moderate to high heterogeneity in the association coefficients in meta-analysis of most of the phenotypes in both ancestry-specific analyses and across ancestries. Different distributions of age, sex, and phenotypes across study cohorts may partially explain the heterogeneity in these associations. Unobserved confounding factors, such as experiment conditions for blood drawing, DNA extraction, and storage may also have contributed to heterogeneity. Finally, we were not able to determine causal relationships between mtDNA CN and metabolic traits due to the crosssectional nature of the study. Future longitudinal studies could help to establish

potential causal pathways between mtDNA CN and these metabolic traits and diseases.

## **Acknowledgments**

Detailed acknowledgment for each cohort is included in Supplemental Materials. In Brief, the authors thank the staff and participants of the Atherosclerosis Risk in Communities study, Cardiovascular Health Study, Coronary Artery Risk Development in Young Adults Study, Framingham Heart Study, Jackson Heart Study, Genetic Epidemiology Network of Arteriopathy Study, Multi-Ethnic Study of Atherosclerosis Study, and UK Biobank for their important contributions. We gratefully acknowledge the studies and participants who provided biological samples and data for TOPMed.

Whole genome sequencing (WGS) for the Trans-Omics in Precision Medicine (TOPMed) program was supported by the National Heart, Lung and Blood Institute (NHLBI). Centralized read mapping and genotype calling, along with variant quality metrics and filtering were provided by the TOPMed Informatics Research Center (3R01HL-117626-02S1; contract HHSN268201800002I). Phenotype harmonization, data management, sampleidentity QC, and general study coordination were provided by the TOPMed Data Coordinating Center (3R01HL-120393-02S1; contract

HHSN268201800001I). Additional phenotype harmonization was performed by the current study (R01AG059727).

The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

#### References

- 1. Voet DVJ, Pratt CW. Fundamentals of Biochemistry. 2nd Edition. John Wiley and Sons, Inc. 2005:pp. 547. ISBN 0471214957. .
- 2. Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial function. Best Pract Res Clin Endocrinol Metab 2012;26:711-23.
- 3. Antico Arciuch VG, Elguero ME, Poderoso JJ, Carreras MC. Mitochondrial regulation of cell cycle and proliferation. Antioxid Redox Signal 2012;16:1150-80.
- 4. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76.
- 5. Misko AL, Sasaki Y, Tuck E, Milbrandt J, Baloh RH. Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration. J Neurosci 2012;32:4145-55.
- 6. Clayton DA, Doda JN, Friedberg EC. The absence of a pyrimidine dimer repair mechanism in mammalian mitochondria. Proc Natl Acad Sci U S A 1974;71:2777-81.
- 7. Seo AY, Joseph AM, Dutta D, Hwang JC, Aris JP, Leeuwenburgh C. New insights into the role of mitochondria in aging: mitochondrial dynamics and more. J Cell Sci 2010;123:2533-42.
- 8. Miller FJ, Rosenfeldt FL, Zhang C, Linnane AW, Nagley P. Precise determination of mitochondrial DNA copy number in human skeletal and cardiac muscle by a PCR-based assay: lack of change of copy number with age. Nucleic Acids Res 2003;31:e61.
- 9. St John JC. Mitochondrial DNA copy number and replication in reprogramming and differentiation. Semin Cell Dev Biol 2016;52:93-101.

- 10. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. New York: Garland Publishing Inc. ISBN 0-8153-3218-1. 1994.
- 11. Moyes CD, Battersby BJ, Leary SC. Regulation of muscle mitochondrial design. J Exp Biol 1998;201:299-307.
- 12. Mengel-From J, Thinggaard M, Dalgard C, Kyvik KO, Christensen K, Christiansen L. Mitochondrial DNA copy number in peripheral blood cells declines with age and is associated with general health among elderly. Hum Genet 2014;133:1149-59.
- 13. Ding J, Sidore C, Butler TJ, et al. Assessing Mitochondrial DNA Variation and Copy Number in Lymphocytes of ~2,000 Sardinians Using Tailored Sequencing Analysis Tools. PLoS Genet 2015;11:e1005306.
- 14. Zhang R, Wang Y, Ye K, Picard M, Gu Z. Independent impacts of aging on mitochondrial DNA quantity and quality in humans. BMC Genomics 2017;18:890.
- 15. Xu FX, Zhou X, Shen F, Pang R, Liu SM. Decreased peripheral blood mitochondrial DNA content is related to HbA1c, fasting plasma glucose level and age of onset in type 2 diabetes mellitus. Diabet Med 2012;29:e47-54.
- 16. Lee HK, Song JH, Shin CS, et al. Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1998;42:161-7.
- 17. Lee JY, Lee DC, Im JA, Lee JW. Mitochondrial DNA copy number in peripheral blood is independently associated with visceral fat accumulation in healthy young adults. Int J Endocrinol 2014;2014:586017.
- 18. Guyatt AL, Burrows K, Guthrie PAI, et al. Cardiometabolic phenotypes and mitochondrial DNA copy number in two cohorts of UK women. Mitochondrion 2018;39:9-19.
- 19. Tin A, Grams ME, Ashar FN, et al. Association between Mitochondrial DNA Copy Number in Peripheral Blood and Incident CKD in the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2016;27:2467-73.
- 20. Scott RA, Lagou V, Welch RP, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nature genetics 2012;44:991-1005.
- 21. Levy D, Ehret GB, Rice K, et al. Genome-wide association study of blood pressure and hypertension. Nat Genet 2009;41:677-87.
- 22. Willer CJ, Schmidt EM, Sengupta S, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet 2013;45:1274-83.
- 23. Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech 2009;2:231-7.
- 24. WHO. Waist Circumference and Waist–Hip Ratio: Report of a WHO Expert Consultation Geneva, 8–11 December 2008 2008.
- 25. Houseman EA, Accomando WP, Koestler DC, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics 2012;13:86.
- 26. Abdi H. Partial least squares regression and projection on latent structure regression (PLS Regression). WIREs Computational Statistics 2010;2:97-106.
- 27. Liu C, Dupuis J, Larson MG, Levy D. Association testing of the mitochondrial genome using pedigree data. Genetic epidemiology 2013;37:239-47.


- 28. Ashar FN, Moes A, Moore AZ, et al. Association of mitochondrial DNA levels with frailty and all-cause mortality. J Mol Med (Berl) 2015;93:177-86.
- 29. Wu IC, Lin CC, Liu CS, Hsu CC, Chen CY, Hsiung CA. Interrelations Between Mitochondrial DNA Copy Number and Inflammation in Older Adults. J Gerontol A Biol Sci Med Sci 2017;72:937-44.
- 30. Knez J, Marrachelli VG, Cauwenberghs N, et al. Peripheral blood mitochondrial DNA content in relation to circulating metabolites and inflammatory markers: A population study. PLoS One 2017;12:e0181036.
- 31. Sharma P. Inflammation and the metabolic syndrome. Indian J Clin Biochem 2011;26:317-8.
- 32. Esposito K, Giugliano D. The metabolic syndrome and inflammation: association or causation? Nutr Metab Cardiovasc Dis 2004;14:228-32.
- 33. Saltiel AR, Olefsky JM. Inflammatory mechanisms linking obesity and metabolic disease. J Clin Invest 2017;127:1-4.
- 34. Paoletti R, Bolego C, Poli A, Cignarella A. Metabolic syndrome, inflammation and atherosclerosis. Vasc Health Risk Manag 2006;2:145-52.
- 35. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High White Blood Cell Count Is Associated With a Worsening of Insulin Sensitivity and Predicts the Development of Type 2 Diabetes. Diabetes 2002;51:455-61.
- 36. Dixon JB, O'Brien PE. Obesity and the white blood cell count: changes with sustained weight loss. Obes Surg 2006;16:251-7.
- 37. Kullo IJ, Hensrud DD, Allison TG. Comparison of numbers of circulating blood monocytes in men grouped by body mass index (<25, 25 to <30, > or =30). Am J Cardiol 2002;89:1441-3.
- 38. Ohshita K, Yamane K, Hanafusa M, et al. Elevated white blood cell count in subjects with impaired glucose tolerance. Diabetes Care 2004;27:491-6.
- 39. Twig G, Afek A, Shamiss A, et al. White blood cells count and incidence of type 2 diabetes in young men. Diabetes Care 2013;36:276-82.
- 40. Orakzai RH, Orakzai SH, Nasir K, et al. Association of white blood cell count with systolic blood pressure within the normotensive range. Journal of Human Hypertension 2006;20:341-7.
- 41. Karthikeyan VJ, Lip GYH. White blood cell count and hypertension. Journal of Human Hypertension 2006;20:310-2.
- 42. Gillum RF, Mussolino ME. White blood cell count and hypertension incidence. The NHANES I Epidemiologic Follow-up Study. J Clin Epidemiol 1994;47:911-9.
- 43. Lai YC, Woollard KJ, McClelland RL, et al. The association of plasma lipids with white blood cell counts: Results from the Multi-Ethnic Study of Atherosclerosis. J Clin Lipidol 2019;13:812-20.
- 44. Short KR, Bigelow ML, Kahl J, et al. Decline in skeletal muscle mitochondrial function with aging in humans. Proc Natl Acad Sci U S A 2005;102:5618-23.
- 45. Kaaman M, Sparks LM, van Harmelen V, et al. Strong association between mitochondrial DNA copy number and lipogenesis in human white adipose tissue. Diabetologia 2007;50:2526-33.

46. Xing J, Chen M, Wood CG, et al. Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst 2008;100:1104-12.


Table 1. Cross-sectional association and meta-analysis of mtDNA CN with metabolic disease phenotypes.

Table 11 91999 99910114 aggestiation and mota analysis of media of with motabolic allocase pro-										
	Traits	Discovery (N=13,400)			Replication: UK Biobank			Meta-analysis of discovery and		
					(N=~39,100)			replication (N=~52,500)		
		OR	95% CI	P-value	OR	95% CI	P-value	OR	95% CI	P-value
10	Obese	1.08	1.03-1.13	5.0e-04	1.15	1.12-1.18	1.6e-30	1.13	1.11-1.16	3.3e-30
me	HTN	1.07	1.03-1.12	1.4e-03	1.04	1.02-1.07	0.00023	1.05	1.03-1.08	4.0e-07
outcomes	Diabetes	1.18	1.01-1.37	0.041	1.04	0.99-1.10	0.10	1.05	1.00-1.10	0.051
Binary o	Hyperlipids	1.04	0.99-1.08	0.11	1.03	1.00-1.06	0.024	1.03	1.00-1.05	0.023
Bin	MetS	1.16	1.06-1.27	1.8e-03	1.13	1.10-1.15	1.1e-24	1.13	1.11-1.16	9.7e-27
		Beta	SE	P-value	Beta	SE	P-value	Beta	SE	P-value
	BMI	0.22*	0.10*	0.028*	0.32	0.023	9.1e-42	0.31	0.023	2.5e-41
Ş	DBP	0.02*	0.20*	0.92*	0.19	0.054	0.00038	0.15	0.049	1.9e-03
outcomes	SBP	0.38	0.19	0.038	0.42	0.094	7.2e-06	0.42	0.085	6.0e-07
outc	FBG	0.067	0.092	0.47	0.20	0.052	2.0e-04	0.16	0.046	5.4e-04
snor	HDL	-0.0097*	0.0099*	0.33*	-0.099	0.069	0.16	-0.012	0.0098	0.21
Continuous	LDL	-0.008*	0.0073*	0.27*	-0.0040	0.0014	0.0045	-0.0027	0.0014	0.059
ပိ	TRIG	0.033	0.0088	1.7e-04	0.023	0.0025	8.6e-21	0.025	0.0022	8.3e-30

The beta estimates are in units of metabolic traits corresponding to one s.d. lower mtDNA-CN. Association analysis of mtDNA CN with metabolic traits was performed in cohorts of European participants (EA) and African American participants (AA) in TOPMed and also in UK Biobank EA participants. Meta-analysis with fixed or random effects inverse variance method was used to summarize the results in EA or AA in TOPMed and the results in discovery and replication. DBP, diastolic blood pressure; SBP, systolic blood pressure; BMI, body mass index; FBG, fasting blood glucose; HDL, high density lipoprotein; Trig, triglyceride. Obese, obesity; HTN, hypertension; Diabetes, Diabetes; MetS, metabolic syndrome. Asterisk (\*) denotes inverse variance random effect meta-analysis.



**Figure 1. Study design**. Association analysis of mtDNA CN with metabolic traits was performed in cohorts of European participants (EA) and American African (AA) in TOPMed and in UK Biobank EA participants. Meta-analysis using fixed or random effects inverse variance method was used to summarize the results in EA or AA in TOPMed. The relationship between age and mtDNA CN was performed in TOPMed and UK Biobank. Primary analysis included age, age<sup>2</sup> (blood pressure traits), sex, and BMI (not in BMI traits). Second analysis included covariates in primary analysis and imputed cell counts. Interaction analysis was performed to investigate whether age and sex modified the relationship between mtDNA CN and metabolic trait



**Figure 2. The relationship of mtDNA CN with age in TOPMED participants.** Scatterplots of mtDNA CN residuals versus age. Y-axis is cohort specific mtDNA CN residuals, x-axis is age. Cohort specific mtDNA CN residuals were obtained by regressing mtDNA CN on blood collection year.




Figure 3. Association analysis and meta-analysis of mtDNA CN with obesity and metabolic syndrome (MetS) in the discovery cohorts of European participants in TOPMed. Fixed effects inverse variance method was used to summarize the results. The odds ratio (OR) corresponds to one s.d. decrease in mtDNA-CN.





Figure 4. Association analysis and meta-analysis of mtDNA CN with continuous metabolic phenotypes in the discovery cohorts of European participants in TOPMed. Fixed effects inverse variance method was used to summarize the results. The effect size estimates are in units of metabolic traits corresponding to one s.d. decrease in mtDNA-CN. BMI, body mass index; HDL, high density lipoprotein; Trig, triglyceride.



**Figure 5.** Comparison of beta of metabolic traits in the participants of European (EA) and American (AA) Americans in TOPMed. DBP, diastolic blood pressure; SBP, systolic blood pressure; BMI, body mass index; FBG, fasting blood glucose; HDL, high density lipoprotein; LDL, low density lipoprotein, Trig, triglyceride. TC, total cholesterol; Obese, obesity; HTN, hypertension; Diabetes, Diabetes; Hyperlipids, hyperlipidemia; MetS, metabolic syndrome.